Fetal exposure to ustekinumab in a pregnant woman with psoriasis

• Autores: M. A. Arias Moya, E. M. Martín Gonzalo, Marta Hernández Segurado, Macarena Bonilla Porras, Eva Castillo Bazán, Francisco Javier Bécares Martínez, Marta Gómez Pérez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 17, Nº. 1, 2015, págs. 9-9
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Psoriasis is a chronic skin disorder characterized by well-demarcated erythematous papules and plaques with a silver scale. Psoriasis commonly occurs in women of reproductive age as three-quarters of patients develop the disease before reaching age 40 years.

    Treatment can be divided into three broad categories: topical therapy, phototherapy,and systemic therapy, which has two subcategories: classic medications and the newer biologic agents.

    Ustekinumab, a monoclonal antibody that targets IL-12 and IL-23, is also classified by the FDA as category B.

    The recent literature reports only two cases of women treated with ustekinumab during pregnancy, one spontaneous abortion at 12 weeks and another healthy childbirth.

    A case of a 39-year-old female patient with psoriasis has been reported and was treated with ustekinumab.

    An unplanned pregnancy took place after her fifth injection in spite of the patient using a form of contraception.

    Her pregnancy reached full term successfully. The infant was born in good conditions,without apparent malformation or symptoms of neonatal illnesses.

    A new case of a healthy new born baby has also been described, but more studies are needed to determine if ustekinumab is safe during pregnancy and if abortion cases in psoriatic women are due to ustekinumab treatment, the disease itself or associated comorbidities